Eli Lilly and Company, commonly referred to as Lilly, is a global leader in the pharmaceutical industry, headquartered in the United Kingdom. Founded in 1876, the company has established a strong presence in major operational regions, including North America, Europe, and Asia, focusing on innovative solutions in diabetes, oncology, immunology, and neuroscience. Lilly is renowned for its pioneering products, such as insulin therapies and cancer treatments, which are distinguished by their commitment to research and development. The company has achieved significant milestones, including the introduction of groundbreaking medications that have transformed patient care. With a robust market position, Eli Lilly continues to be recognised for its contributions to healthcare, consistently ranking among the top pharmaceutical companies worldwide.
How does Eli Lilly and Company's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Other Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Eli Lilly and Company's score of 55 is higher than 98% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Eli Lilly and Company reported total carbon emissions of approximately 182,000,000 kg CO2e for Scope 1, 345,000,000 kg CO2e for Scope 2, and 5,139,500,000 kg CO2e for Scope 3, bringing their total emissions to about 5,666,500,000 kg CO2e. The company has set an ambitious target to achieve carbon neutrality in its operations by 2030, encompassing all scopes of emissions. This commitment reflects Lilly's dedication to reducing its carbon footprint and addressing climate change proactively. In previous years, emissions have shown fluctuations, with 2022 emissions recorded at approximately 171,000,000 kg CO2e for Scope 1, 374,000,000 kg CO2e for Scope 2, and 5,139,500,000 kg CO2e for Scope 3. The company has consistently disclosed emissions across all three scopes, demonstrating transparency in its environmental impact reporting. Eli Lilly's ongoing initiatives and targets align with industry standards for climate action, reinforcing its commitment to sustainability and responsible corporate practices.
Access structured emissions data, company-specific emission factors, and source documents
2007 | 2010 | 2011 | 2012 | 2013 | 2014 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | 527,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 2 | 1,310,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 3 | 14,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Eli Lilly and Company is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.